secwatch.observer — SEC 8-K summary
======================================

Issuer:     Entrada Therapeutics, Inc. (TRDA)
CIK:        0001689375
Form:       8-K
Filed at:   2026-06-10T20:06:08+00:00
Accession:  0001104659-26-072326
Event type: other_material
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Entrada shareholders approve plan amendments including pre-funded warrants in evergreen formulas
--------------------------------------------------------------------------------

- Stockholders elected Peter S. Kim, Ph.D. and Bernhardt Zeiher, M.D. as Class II directors; 22.2M and 22.3M votes for, respectively.
- Ratified Ernst & Young as independent auditor for FY 2026 with 33.1M votes for.
- Approved Amendment No. 1 to 2021 Stock Option and Incentive Plan: pre-funded warrants count in evergreen share increase calculation.
- Approved Amendment No. 1 to 2021 ESPP: similarly includes pre-funded warrants in share reserve formula, plus share cap of 557,524 or 1% of outstanding shares.
- 38.8M shares outstanding as of record date; 33.2M shares represented at the meeting.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1689375/000110465926072326/0001104659-26-072326-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1689375/000110465926072326/tm2617532d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-072326

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer